Post-Brexit, UK ditches the strict EU regulation for genetic engineering: in future, gene-edited crops will be assessed just like any other new variety, the government said.
A comparison of immune correlates of AstraZeneca’s Phase II/III COVID-19 vaccine trial shows what antibodiy titer is required to prevent symptomatic disease.
AstraZeneca has teamed up with RNA vaccine and therapeutic developer VaxEquity, investing US$195m in milestone payments alone.
The EIF has invested €25m in the Prague-based i&i Biotech Fund I to boost biomedical tech transfer in Austria and Eastern Europe.
Boehringer Ingelheim has acquired Texan biotech Abexxa Biologics Inc., further expanding its cancer immunotherapy pipeline.
Following the $39bn Alexion buy-out completed in July, AstraZeneca plc announced it will invest €307m in the company’s producion site near Dublin.
Bayer AG has joined forces with young Danish biotech Gubra ApS in a research collaboration and license agreement for the development of peptide therapeutics to treat cardiorenal diseases.
The Novo Nordisk Foundation is investing US$47.5m into a research collaboration with the Broad Institute of MIT and Harvard, intending to dive into the disease mechanisms of diabetes and obesity.
UK-based DNA synthesis specialist Touchlight Ltd has extended a funding round to a current aggregate total of US $125m.
Royal DSM is backing Meatable, the cultivated meat start-up, in order to develop growth media for cultivated meat.